Radiopharmaceutical Device Development Explained

Two men, Nick A. (left) and Nigel (right), sit at a white table, engaging in a lively and friendly conversation. Both wear checkered shirts and lavalier microphones, suggesting a filmed discussion or interview. Nick holds tissue samples in one hand and gestures animatedly, while Nigel smiles in response. Each has a white mug labeled with their name and a purple star logo. The background is a bright white, creating a clean and professional studio setting.
Resources

Radiopharmaceutical Device Development Explained

Sector: Diagnostics
Topic: Bio Break
YouTube video thumbnail

Radiopharmaceutical device development is gaining momentum as medical teams explore new frontiers in diagnostic imaging and cancer treatment. In this episode of Bio Break, Nigel and Nick dive into how radioisotopes are used in both therapeutic and imaging applications—and what it means for engineers designing devices that handle radiation safely.

Nigel explains how these radioactive compounds—like radiolabeled glucose—can help detect cancer by highlighting areas of high metabolic activity in the body. The technique is based on how tumors often consume more glucose than surrounding tissue. So when tagged with a tracer like FDG (fluorodeoxyglucose), those hotspots become visible.

Nick shares his own experience using these radiopharmaceuticals in drug delivery trials. He describes a study comparing radiolabeled compounds that either do or do not cross the blood-brain barrier. By using FDG as a positive control and FLT (fluorothymidine) as a negative control, his team was able to track how a drug reached—or failed to reach—the brain.

As device developers, the implications are clear. Designing tools that safely handle radioactive materials requires special care. From the initial generator to the final “daughter” isotopes used in patients, radiopharmaceutical workflows are complex, fast-moving, and full of potential.

For medical device innovators, this space offers exciting opportunities—especially as demand for targeted therapies and precise imaging continues to grow.

Learn more about StarFish Medical.

A vial of orange liquid with a radiation symbol and a syringe sit on a reflective metal surface in front of a large medical imaging machine. The overlay text reads: "Radioactive. On Purpose?" in bold black font on a white rounded background.

Radiopharmaceutical Device Development Explained

Radiopharmaceutical device development is gaining momentum as medical teams explore new frontiers in diagnostic imaging and cancer treatment.

A gloved hand holds a COVID-19 lateral flow test in front of a white bathroom sink and tiled wall. Overlay text reads: ‘From ELISA to DIY?’ in bold white font on a black background.

ADLM Diagnostics Innovation and COVID Testing

Nick Allan and Nigel Syrotuck reflect on recent ADLM diagnostics innovation and how it has shaped the future of clinical testing.

loved hand holding a blood vial in front of blurred Chicago skyline. Overlay text says ‘From vial… To Chicago?’ in bold white font on black background.

Laboratory Diagnostics Showcase at ADLM 2025

Each summer, the laboratory diagnostics showcase hosted by the Association for Diagnostics & Laboratory Medicine (ADLM) draws industry leaders to Chicago.

Thumbnail showing a vial of clear contrast agent on the left, with a red dotted arrow pointing to an X-ray image of a skull displayed on a tablet held by a person in a white coat. Overlay text reads “Not approved here?” in bold black and white text.

Understanding Contrast Agents in Imaging

Nigel and Nick explore how contrast agents in imaging support medical device trials and diagnostics. While bones appear clearly in standard X-rays, soft tissues like those in the nasal cavity often require contrast agents to become visible.